Genmab A/S ADS (GMAB) Stock: Buy, Sell, or Hold?
GMAB - Genmab A/S ADS
$43.79
3.79 (9.47%)
▲
5d:
+18.35%
30d:
+25.72%
90d:
+52.05%
WAIT
LOW Confidence
Analysis Updated: Oct 23, 2026 12:00 AM ET
Earnings: Nov 05, 2026
11d
Get Alerted When GMAB Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR BETTER ENTRY: GMAB is 13.2% above its trading range ($38.68). Market expects 17.2% annual growth, but current price leaves little margin for error. While momentum could continue, risk/reward favors waiting for a pullback.
⏸️ WAIT FOR BETTER ENTRY: GMAB is 13.2% above its trading range ($38.68). Market expects 17.2% annual growth, but current price leaves little margin for error. While momentum could continue, risk/reward favors waiting for a pullback.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$52.81
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$32.79
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 17.9x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: GMAB is currently trading at $43.79, which is considered extended relative to its 30-day fair value range of $34.24 to $38.68. From a valuation perspective, the stock is trading at a premium (Forward PE: 28.9) compared to its historical average (17.9). At these levels, the market is pricing in 17.2% annual earnings growth.
Technical Outlook: Technically, GMAB is in a strong uptrend. The price is approaching resistance at $44.34. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 9.5% recently.
Market Sentiment: GMAB scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, GMAB is in a strong uptrend. The price is approaching resistance at $44.34. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 9.5% recently.
Market Sentiment: GMAB scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$34.24 -
$38.68
Company Quality Score
41/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
22.4%
All Signals
- BEARISH: Price significantly overextended (+13.2% above its trading range)
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+9.5%)
- NEUTRAL: Near Wall St target ($45.04)
- BULLISH: Expecting earnings turnaround to 17.2% growth with 24.9% revenue growth
- WARNING: Composite score 41/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$34.24 -
$38.68
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$36.13
Resistance Level
$44.34
Current Trend
Strong Uptrend
Technical data as of
Oct 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
28.90
Wall Street Target
$45.04
(+2.8%)
Revenue Growth (YoY)
24.9%
Earnings Growth (YoY)
-9.4%
Profit Margin
19.1%
Valuation Premium vs History
+17.2% premium
PE vs Historical
28.9 vs 17.9
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+17.2%
(market-implied from PE analysis)
1-Year Target
$51.32
(+17%)
2-Year Target
$60.15
(+37%)
3-Year Target
$70.49
(+61%)
3-Yr Target (if PE normalizes)
(PE: 29→18)
PE COMPRESSION
$43.66
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 28.9, Growth: 29.5%)
$95.07
(+117%)
Base:
(SPY PE: 19.9, Growth: 29.5%)
$65.32
(+49%)
Bear:
(PE: 16.9, Growth: 29.5%)
$55.53
(+27%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (31x PE), but valuation improves significantly next year (29x PE) as earnings recover.
Trailing PE: 31.25 | Current EPS (TTM): $1.28
Bull Case
$52.08
(+19%)
Analyst growth 18.4%, PE expands to 34.4
Base Case
$47.34
(+8%)
Market implied 18.4%, PE stable at 31.3
Bear Case
$27.20
(-38%)
Severe decline -20.0%, PE contracts to 26.6
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: October 24, 2026 1:59 AM ET
Data refreshes hourly during market hours. Next update: 2:59 AM
Data refreshes hourly during market hours. Next update: 2:59 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is GMAB showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$369 | 52 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
27 analysts |
$436 | 38 SELL |
|
ASND
Ascendis Pharma AS |
STRONG BUY
21 analysts |
$307 | 51 HOLD |
|
RYTM
Rhythm Pharmaceuticals I… |
STRONG BUY
18 analysts |
$144 | 75 BUY |
|
PVLA
Palvella Therapeutics, I… |
STRONG BUY
15 analysts |
$231 | 60 HOLD |
